TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.  

Physicians and researchers complete thousands of clinical trials each year, but some findings prove far more significant than others. For cardiologist Dharmesh Patel, MD, the results of the SMART trial have changed the way he’s managing and recommending treatment for women with symptomatic severe aortic stenosis.

Some of the most talked about data at ACC.24 were the results of a late-breaking clinical trial comparing different transcatheter aortic valve replacement (TAVR) valves in patients with a small aortic annulus. 

Munster, Indiana, is a thriving suburb 30 miles south of the heart of Chicago. It’s a place where the locals like to stay local, especially when it comes to healthcare. Patients in the area often turn to 454-bed Community Hospital, one of three acute-care hospitals part of Powers Health.